Pazopanib: in advanced soft tissue sarcoma (Q42715298)

5 November 2017

title

Pazopanib: in advanced soft tissue sarcoma (English)

1 reference

5 November 2017

1 reference

ChEBI release 2020-05-28

1

Emma D Deeks

1 reference

5 November 2017

publication date

1 November 2012

1 reference

5 November 2017

1 reference

5 November 2017

volume

72

1 reference

5 November 2017

issue

16

1 reference

5 November 2017

page(s)

2129-2140

1 reference

Diagnosis and management of soft tissue sarcoma

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Soft-tissue sarcomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Pazopanib in the treatment of soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

The molecular biology of soft-tissue sarcomas and current trends in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Angiogenesis inhibition in non-GIST soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Effect of pazopanib on tumor microenvironment and liposome delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209950-000000000-00000

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23072642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23072642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Guidelines for the management of soft tissue sarcomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23072642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11209950-000000000-00000

1 reference

Dimensions Publication ID

5 November 2017

1022980986

0 references

1 reference